Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.
Vannucchi AM, Sordi B, Morettini A, Nozzoli C, Poggesi L, Pieralli F, Bartoloni A, Atanasio A, Miselli F, Paoli C, Loscocco GG, Fanelli A, Para O, Berni A, Tassinari I, Zammarchi L, Maggi L, Mazzoni A, Scotti V, Falchetti G, Malandrino D, Luise F, Millotti G, Bencini S, Capone M, Piccinni MP, Annunziato F, Guglielmelli P; RUXO-COVID Study Group.
Vannucchi AM, et al. Among authors: annunziato f.
Leukemia. 2021 Apr;35(4):1121-1133. doi: 10.1038/s41375-020-01018-y. Epub 2020 Aug 19.
Leukemia. 2021.
PMID: 32814839
Free PMC article.
Clinical Trial.